A detailed history of Affinity Capital Advisors, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Affinity Capital Advisors, LLC holds 3,410 shares of ABBV stock, worth $580,893. This represents 0.13% of its overall portfolio holdings.

Number of Shares
3,410
Previous 3,402 0.24%
Holding current value
$580,893
Previous $583,000 15.44%
% of portfolio
0.13%
Previous 0.12%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

BUY
$163.84 - $199.33 $1,310 - $1,594
8 Added 0.24%
3,410 $673,000
Q2 2024

Aug 13, 2024

SELL
$154.79 - $180.76 $3,869 - $4,519
-25 Reduced 0.73%
3,402 $583,000
Q1 2024

Apr 12, 2024

BUY
$159.82 - $182.1 $5,913 - $6,737
37 Added 1.09%
3,427 $624,000
Q4 2023

Jan 11, 2024

SELL
$137.6 - $154.97 $7,568 - $8,523
-55 Reduced 1.6%
3,390 $525,000
Q3 2023

Oct 10, 2023

BUY
$133.59 - $154.65 $23,111 - $26,754
173 Added 5.29%
3,445 $513,000
Q2 2023

Jul 13, 2023

BUY
$132.51 - $164.9 $7,023 - $8,739
53 Added 1.65%
3,272 $440,000
Q1 2023

Apr 11, 2023

SELL
$144.61 - $166.54 $4,338 - $4,996
-30 Reduced 0.92%
3,219 $513,000
Q4 2022

Jan 18, 2023

BUY
$138.31 - $165.87 $829 - $995
6 Added 0.19%
3,249 $0
Q3 2022

Oct 12, 2022

BUY
$134.21 - $153.93 $671 - $769
5 Added 0.15%
3,243 $435,000
Q2 2022

Jul 11, 2022

SELL
$137.62 - $174.96 $5,917 - $7,523
-43 Reduced 1.31%
3,238 $496,000
Q1 2022

Apr 19, 2022

BUY
$131.98 - $163.75 $7,126 - $8,842
54 Added 1.67%
3,281 $532,000
Q4 2021

Jan 31, 2022

BUY
$107.43 - $135.93 $107 - $135
1 Added 0.03%
3,227 $437,000
Q3 2021

Oct 28, 2021

BUY
$106.4 - $120.78 $106 - $120
1 Added 0.03%
3,226 $348,000
Q2 2021

Aug 13, 2021

BUY
$105.21 - $117.21 $24,829 - $27,661
236 Added 7.9%
3,225 $363,000
Q1 2021

Apr 19, 2021

BUY
$102.3 - $112.62 $305,774 - $336,621
2,989 New
2,989 $323,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $301B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Affinity Capital Advisors, LLC Portfolio

Follow Affinity Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Capital Advisors, LLC with notifications on news.